TB-500 Oral Bioavailability: Why Injection Remains the Only Studied Route
Does oral TB-500 work? A look at peptide oral bioavailability research, why TB-500's size and structure make oral absorption unlikely, and how it compares to injectable and intranasal routes.
> Research disclaimer: This article discusses peptide pharmacology and administration-route research for informational purposes only. TB-500 is sold as a research chemical, is not FDA-approved, and nothing here is medical advice.
Does Oral TB-500 Work?
Quick answer: No meaningful evidence supports oral TB-500 as a functional route of administration. TB-500 is a 43-amino-acid peptide, and peptides of that size are broken down by digestive enzymes (pepsin, trypsin, chymotrypsin) before they can be absorbed intact, and what survives digestion is largely blocked by the intestinal lining, which isn't built to pass molecules this large into the bloodstream. This isn't a TB-500-specific problem — it's the same barrier that affects almost all unmodified peptide drugs, and it's why the research and supplier community has settled on subcutaneous injection as the only route with a real evidence base behind it.
If you've seen "oral TB-500" capsules or tablets marketed anywhere, the honest framing is that the underlying pharmacology makes it very unlikely they deliver meaningfully intact peptide into circulation, regardless of what the product claims.
---
Why Peptides Struggle With Oral Delivery
Oral bioavailability is a chronic problem across the entire peptide drug class, not something unique to research chemicals. Three barriers compound on top of each other:
Enzymatic degradation. The stomach and small intestine are lined with proteolytic enzymes whose entire job is breaking peptide bonds — the exact bonds that hold a 43-amino-acid chain like thymosin beta-4 together. Pepsin starts the process in the stomach; trypsin, chymotrypsin, and other pancreatic enzymes finish it in the small intestine. A peptide swallowed as a capsule is, from the digestive system's perspective, indistinguishable from a piece of food protein to be broken down into amino acids.
Poor intestinal permeability. Even a peptide fragment that survived digestion intact faces the intestinal epithelium — a barrier specifically built to let small molecules (sugars, amino acids, some drugs under roughly 500 Da) through while excluding larger ones. TB-500's molecular weight (approximately 4,963 Da for the free acid form) is roughly ten times that threshold, well outside the size range that passively crosses the gut wall in meaningful quantity.
First-pass hepatic metabolism. Anything absorbed from the small intestine travels through the portal vein to the liver before reaching general circulation. The liver is metabolically aggressive toward peptides and would degrade much of whatever fraction survived digestion and absorption, before it ever reached an injury site.
Each of these barriers alone would meaningfully limit oral bioavailability. Stacked together, they're why unmodified peptide oral bioavailability figures across the drug-development literature are typically well under 1% — and TB-500 has none of the chemical modifications (specialized carriers, absorption enhancers, enzyme-inhibiting co-formulations) that some oral peptide drugs use to partially overcome this.
---
How Other Oral Peptide Drugs Solve This — and Why TB-500 Doesn't Have That
A few peptide drugs have reached the market in oral form, and it's worth understanding what that took, because it highlights how far "oral TB-500" is from anything comparable.
Oral semaglutide (marketed as Rybelsus) is the clearest example: it's co-formulated with SNAC (salcaprozate sodium), an absorption enhancer that locally raises stomach pH and increases membrane permeability around the tablet as it dissolves. Even with that engineering, oral semaglutide's bioavailability is roughly 0.4-1%, compared to near-complete absorption for the injectable form — the tablet dose has to be dramatically higher to compensate.
No commercially available "oral TB-500" product uses anything comparable. Research-chemical vendors selling oral capsules or tablets are, as far as publicly available information shows, not using absorption-enhancing co-formulations, enteric coatings designed for peptide protection, or any documented delivery technology — they're putting lyophilized peptide powder into a capsule shell, which does nothing to address any of the three barriers described above.
---
Oral vs. Other TB-500 Administration Routes
| Route | Bioavailability basis | Evidence level |
|---|---|---|
| Subcutaneous injection | Bypasses GI tract and first-pass metabolism entirely | Standard route in nearly all TB-500 research and community protocols |
| Intramuscular injection | Same bypass, potentially faster local absorption | Used less often, but mechanistically sound |
| Intranasal | Crosses nasal mucosa directly, bypasses GI tract | Emerging interest, but TB-500's larger size (vs. smaller peptides like BPC-157) creates formulation challenges — see the intranasal research guide |
| Oral | Must survive digestion and cross intestinal wall | No credible evidence of meaningful bioavailability; not used in any published TB-500 research |
The subcutaneous vs. intramuscular guide covers the two injection routes in detail — both share the fundamental advantage that they route the peptide directly into tissue or bloodstream, sidestepping everything discussed above.
---
What's Genuinely Unknown
---
Frequently Asked Questions
Can I take TB-500 as a pill or capsule instead of injecting it?
You can purchase products marketed that way, but the underlying peptide pharmacology strongly suggests minimal intact peptide would reach circulation through that route. No published research supports oral TB-500 as bioequivalent, or even meaningfully active, compared to injection.
Why do some vendors sell oral TB-500 products if it doesn't work?
Likely because oral products are easier to sell, ship, and use than injectables, and because most buyers don't have a way to verify bioavailability themselves. The absence of any disclosed absorption-enhancing formulation in these products is the practical tell that they aren't addressing the underlying bioavailability problem.
Is intranasal TB-500 a better alternative to oral?
Mechanistically, yes — nasal mucosa allows more direct absorption than the GI tract, bypassing digestion entirely. But TB-500's larger molecular size compared to peptides like BPC-157 still creates real formulation and consistency challenges for intranasal delivery, which the nasal spray research guide covers in more depth. It's a more plausible route than oral, not a fully validated one.
Does molecular weight alone determine whether a peptide can be taken orally?
It's the single biggest factor, but not the only one. Enzymatic stability, charge, and whether the formulation includes absorption enhancers all matter too. TB-500's roughly 4,963 Da size puts it well outside the range where passive oral absorption is plausible, and it lacks any of the co-formulation technology used by the peptide drugs that have achieved workable oral bioavailability.
Would injecting a smaller fragment of TB-500 improve oral bioavailability?
Smaller peptide fragments generally do better orally than larger ones, which is part of why the mechanism of action research on Ac-LKKTETQ (the shorter active fragment discussed in the Fragment 17-23 guide) sometimes comes up in this context. But smaller size reduces one barrier, not all three, and no oral bioavailability data exists for that fragment either.
Sourcing Quality Research Peptides
Because oral TB-500 products lack a credible bioavailability basis, researchers focused on injectable protocols should prioritize vendors with verifiable third-party testing rather than delivery-format novelty. Apollo Peptide Sciences provides third-party tested, research-grade injectable TB-500 with published certificates of analysis.
---
Related: TB-500 Subcutaneous vs. Intramuscular Guide · TB-500 Nasal Spray Research · TB-500 Mechanism of Action · TB-500 Fragment 17-23 Guide